Gilead Sciences, Inc. (NASDAQ:GILD) Position Reduced by California Public Employees Retirement System

California Public Employees Retirement System decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,087,177 shares of the biopharmaceutical company's stock after selling 2,589 shares during the quarter. California Public Employees Retirement System owned approximately 0.49% of Gilead Sciences worth $562,273,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company's stock.

Remove Ads

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Stock Performance

GILD stock traded down $0.77 during trading on Tuesday, reaching $111.28. The company had a trading volume of 6,284,006 shares, compared to its average volume of 7,287,905. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $138.58 billion, a price-to-earnings ratio of 300.76, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm has a 50-day simple moving average of $105.88 and a 200-day simple moving average of $95.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.